Broad Discovery Series: The story behind a new therapy for lung cancer patients

Name: Broad Discovery Series: The story behind a new therapy for lung cancer patients
Start: 2026-02-24T18:00:00-05:00
Location: Broad Institute of MIT and Harvard

Schedule

Tue, 24 Feb, 2026 at 06:00 pm

UTC-05:00

Location

Broad Institute of MIT and Harvard | Cambridge, MA

Join us for a hybrid Broad Discovery Series talk, "The story behind a new therapy for lung cancer patients."
Date: Tuesday, February 24 2026 6:00 pm (ET)
Register at: https://broadinstitute.swoogo.com/discovery26/
In the early 2000s, Broad Institute researchers found that the EGFR protein is mutated in lung cancer, sparking a revolution in targeted cancer treatment. But not all lung tumors respond to such treatments, leaving many patients with few options. In this Broad Discovery Series event, Heidi Greulich and Matthew Meyerson will describe the 20-year history of sevabertinib, a new lung cancer drug (and the first FDA-approved drug born of Broad science) that blocks both EGFR and the related HER2 protein; talk about the unmet need it fulfills, discuss the unique partnership behind its development, and explore drug development's evolving challenges.

This Broad Discovery Series talk will be held both in person and virtually. Those joining us in person are invited to a reception after the talk.

Register at: https://broadinstitute.swoogo.com/discovery26/

The Broad Discovery Series is a program of the Broad Discovery Center, an active, public educational space that showcases how researchers at the Broad Institute and their colleagues around the world are tackling some of the toughest questions in biomedicine, gaining a deeper understanding of human health and disease, and translating that insight into new approaches for treatments. Learn more about the Broad Discovery Center at broaddiscoverycenter.org.